Pancreatic Cancer Research

ResearcherQingdao UniversityActive in the last 2 years

Zhen Tan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6188-209X; OpenAlex author ID A5052990671. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 5 papers · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 4 papers · 2026: 1 paper

Papers 18

  1. The CHPT-pSTAT3-SLC7A11 signaling axis controls progression and ferroptosis susceptibility of pancreatic cancer. Co-author DOI 10.1016/j.tranon.2025.102624↗
  2. m6A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis. Co-author DOI 10.1038/s41419-025-08049-2↗
  3. Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. Co-author DOI 10.1053/j.gastro.2025.03.019↗
  4. Dense stroma activates the TGF-β1/FBW7 axis to induce metabolic subtype switching in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000002242↗
  5. Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-334361↗
  6. m6A reader YTHDF2 orchestrates CD8+ T cell infiltration to promote pancreatic cancer progression and predicts clinical outcome. Co-author DOI 10.1016/j.intimp.2024.113079↗
  7. CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-23-3596↗
  8. LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification. Co-author DOI 10.1007/s00432-022-04400-8↗
  9. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2022-329349↗
  10. RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner. Co-author DOI 10.1038/s41388-022-02306-w↗
  11. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00018-021-03866-y↗
  12. Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis. Co-author DOI 10.1186/s12943-021-01400-z↗
  13. Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.674897↗
  14. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. Co-author DOI 10.3390/ijms222010944↗
  15. Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment. Co-author DOI 10.7150/thno.56174↗
  16. Hypoxia: a barricade to conquer the pancreatic cancer. Co-author DOI 10.1007/s00018-019-03444-3↗
  17. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction. Co-author DOI 10.18632/aging.104134↗
  18. The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It calls for more careful evaluation. Co-author DOI 10.1002/jso.25690↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 17 shared papers, 2019–2026 · strength 2.84
  2. Chen Liang · 13 shared papers, 2019–2026 · strength 2.09
  3. Si Shi · 13 shared papers, 2019–2025 · strength 1.92
  4. Qingcai Meng · 11 shared papers, 2020–2026 · strength 1.80
  5. Jin Xu · 11 shared papers, 2020–2025 · strength 1.66
  6. Jie Hua · 10 shared papers, 2020–2026 · strength 1.58
  7. Zeyin Rong · 7 shared papers, 2021–2026 · strength 1.33
  8. Wei Wang · 6 shared papers, 2021–2026 · strength 1.02
  9. Jianhui Yang · 4 shared papers, 2021–2026 · strength 0.84
  10. Mingming Xiao · 3 shared papers, 2025 · strength 0.65
  11. Rong Tang · 3 shared papers, 2023–2025 · strength 0.57
  12. Xiaomeng Liu · 3 shared papers, 2022–2025 · strength 0.53
  13. Bo Zhang · 3 shared papers, 2020–2023 · strength 0.45
  14. Qiong Du · 2 shared papers, 2025 · strength 0.41
  15. Jin Xu · 2 shared papers, 2025 · strength 0.41
  16. Miaoyan Wei · 2 shared papers, 2020–2026 · strength 0.37
  17. Jin Xu · 1 shared paper, 2026 · strength 0.27
  18. Yiyin Zhang · 2 shared papers, 2020–2023 · strength 0.26
  19. Jiang Liu · 2 shared papers, 2020–2021 · strength 0.24
  20. Xu He · 1 shared paper, 2025 · strength 0.24
  21. Jing Yang · 1 shared paper, 2025 · strength 0.24
  22. Mengqi Song · 1 shared paper, 2024 · strength 0.23
  23. Kai Ma · 1 shared paper, 2024 · strength 0.23
  24. Weidong Guo · 1 shared paper, 2024 · strength 0.23
  25. Heng Zhu · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.